Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study

Long-term outcomes of edaravone in amyotrophic lateral sclerosis in South Korea: 72-week observational study

Abstract Background Amyotrophic lateral sclerosis (ALS) is a lethal neurodegenerative disease characterized by the gradual loss of upper and lower motor neurons that leads to progressive muscle atrophy and weakness. Edaravone, a free-radical scavenger, was approved as an ALS treatment in 2015 in Sou...

Full description

Bibliographic Details
Main Authors: Jin-Mo Park, Donghwi Park, Hyung-Jun Kim, Jin-Sung Park
Format: Article
Language:English
Published: BMC 2022-07-01
Series:BMC Neurology
Subjects:
Edaravone
Amyotrophic lateral sclerosis
Adverse effect
Safety
Online Access:https://doi.org/10.1186/s12883-022-02788-x

Similar Items

Similar Items